PolyMedix to Host Webcast on Heparin, Bleeding Complications, & PolyMedix's PMX-60056 Reversing Agent

PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company developing acute care therapeutic drug products for infectious diseases and cardiovascular disorders, will host a webcast event on Heparin, Bleeding Complications, and PolyMedix’s PMX-60056 Heparin Reversing Agent on Tuesday, December 15, 2009 at 10:00 am EST.

PolyMedix executives will discuss the use of anticoagulants heparin and low molecular weight heparins (LMWH), the heparin reversing agent protamine, potential bleeding complications, and the opportunity for a new fast-acting, synthetic heparin-reversing agent. The webcast will be available to interested parties. Those interested in listening to management's discussion, may access an audio portion of the event by dialing (877) 407-0778 for domestic participants, and (201) 689-8565 for international participants.

The anticoagulant heparin is routinely used in acute surgical applications to prevent life-threatening blood clots. After surgery, patients are treated with protamine which is currently the only agent approved to reverse the action of heparin. Protamine may have potential drawbacks including bleeding complications and allergic reactions. In addition, protamine has not been approved to reverse low molecule-weight heparins, which are prescribed to patients undergoing long-term care outside the hospital setting.

PolyMedix’s lead heptagonist compound PMX-60056 is a new fast-acting, synthetic compound under development for the reversal of heparin and LMWH. PolyMedix recently completed a successful Phase 1B pilot proof-of-concept human clinical study with PMX-60056. The results demonstrated that PMX-60056 completely reversed the anticoagulant effects of heparin and normalized blood clotting time in human subjects in less than 10 minutes, and that no serious adverse events occurred during the study.

About PolyMedix, Inc.
PolyMedix is a publicly traded emerging biotechnology company focused on the development of novel drugs and biomaterials for the treatment of infectious diseases and acute cardiovascular disorders. PolyMedix’s compounds are based on biomimetics: non-peptide small molecule drug candidates that mimic the activity of proteins. The Company’s antibiotic compounds, including PMX-30063 – small molecule mimetics of human host-defense proteins – have a mechanism of action distinct from those of current antibiotic drugs, a mechanism that is intended to make bacterial resistance unlikely to develop. The Company’s goal is to develop these as rapidly acting antibiotics for serious systemic and local infections. The Company plans to continue the development of polymeric formulations as antimicrobial biomaterials, which can be used as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. The Company’s heptagonist compounds, including PMX-60056, reverse the activity of both heparin and Low Molecular Weight Heparins, with the goal of developing an antagonist drug for LMWHs, and that is safer and easier to use than currently approved therapy for heparin. For more information, please visit PolyMedix.

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause PolyMedix’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. PolyMedix has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal”, “potential,” “may,” ”suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements, PolyMedix’s compounds may not enter or successfully complete clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these factors is included in PolyMedix’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.